Highlights Divi’s clocked its first quarterly sales drop in years. Gland Pharma saw steady decline in profit margins Performance hit by high costs, delay in projects and slowing COVID drug sales Companies are adding new projects and capacities whose benefits are expected to materialise from the next fiscal year or so Divi’s Laboratories and Gland Pharma, which thrived on the business to business (B2B) model, have hit a speed breaker. Shares of both these companies slumped after the September quarter results. Divi’s clocked...
Moneycontrol Pro Panorama | Will the MPC signal a pause?
Feb 6, 2023 / 03:05 PM IST
In today’s edition of Moneycontrol Pro Panorama: Market outlook for automakers gets a lift, will GST Council come up with wider ...Read Now
To read the full story, Subscribe to Moneycontrol PRO
Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience
Already a member? Sign in
Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to
Ad free experience
Experience a non-intrusive navigation and faster response in the ad free mode
Access to 230+ exclusive stories per month from our editorial and Experts
Have a Global edge with access to content from world renowned experts and journalist
Access to 40+ weekly investment ideas including 4 daily technical calls
Exclusive access to live webinars from market experts on trading and investment strategies
Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.
Get upto 50% discount on limited period offers